BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38294612)

  • 21. Rb Loss and
    Hijioka S; Hosoda W; Matsuo K; Ueno M; Furukawa M; Yoshitomi H; Kobayashi N; Ikeda M; Ito T; Nakamori S; Ishii H; Kodama Y; Morizane C; Okusaka T; Yanagimoto H; Notohara K; Taguchi H; Kitano M; Yane K; Maguchi H; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Kawaguchi Y; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Yoshida T; Hara K; Imamura M; Furuse J; Yatabe Y; Mizuno N
    Clin Cancer Res; 2017 Aug; 23(16):4625-4632. PubMed ID: 28455360
    [No Abstract]   [Full Text] [Related]  

  • 22. The evolving role of imaging for small bowel neuroendocrine neoplasms: estimated impact of imaging and disease-free survival in a retrospective observational study.
    Kim S; Marcus R; Wells ML; Sheedy SP; Hansel SL; Bruining DH; Barlow JM; Carter RE; Lee YS; Johnson MP; Fidler JL; Goenka AH; McCollough CH; Fletcher JG
    Abdom Radiol (NY); 2020 Mar; 45(3):623-631. PubMed ID: 31980866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States.
    Kessel E; Naparst M; Alpert N; Diaz K; Ahn E; Wolin E; Taioli E; Kim MK
    Pancreas; 2021 Jan; 50(1):29-36. PubMed ID: 33370020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome.
    Dioguardi Burgio M; Cros J; Panvini N; Depoilly T; Couvelard A; Ruszniewski P; de Mestier L; Hentic O; Sauvanet A; Dokmak S; Faccinetto A; Ronot M; Vilgrain V
    Eur Radiol; 2021 Nov; 31(11):8671-8681. PubMed ID: 33977308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms.
    Frilling A; Clift AK; Frampton AE; Bomanji J; Kaemmerer D; Al-Nahhas A; Alsafi A; Kidd M; Modlin IM; Hoersch D; Baum RP
    Int J Med Sci; 2021; 18(10):2166-2175. PubMed ID: 33859524
    [No Abstract]   [Full Text] [Related]  

  • 27. The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.
    Wen J; Chen J; Liu D; Xu X; Fan M; Zhang Z
    Neuroendocrinology; 2020; 110(5):364-376. PubMed ID: 31357196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Racial Disparities in Resection of Early Stage Non-Small Cell Lung Cancer: Variability Among Surgeons.
    Ezer N; Mhango G; Bagiella E; Goodman E; Flores R; Wisnivesky JP
    Med Care; 2020 Apr; 58(4):392-398. PubMed ID: 31895307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Race and health disparities in patient refusal of surgery for early-stage non-small cell lung cancer: a SEER cohort study.
    Mehta RS; Lenzner D; Argiris A
    Ann Surg Oncol; 2012 Mar; 19(3):722-7. PubMed ID: 21947698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Pancreatic Cancer: An NCDB Cohort Study.
    Tohme S; Kaltenmeier C; Bou-Samra P; Varley PR; Tsung A
    Ann Surg Oncol; 2018 Nov; 25(12):3427-3435. PubMed ID: 30043318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronological improvement of pancreatectomy for resectable but advanced pancreatic neuroendocrine neoplasms.
    Takamoto T; Nara S; Ban D; Mizui T; Murase Y; Esaki M; Shimada K
    Pancreatology; 2022 Dec; 22(8):1141-1147. PubMed ID: 36404199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of racial disparities in early-stage lung cancer treatment.
    Wolf A; Alpert N; Tran BV; Liu B; Flores R; Taioli E
    J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1670-1679.e4. PubMed ID: 30685165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated With Patient's Refusal of Recommended Cancer Surgery: Based on Surveillance, Epidemiology, and End Results.
    Hu X; Ye H; Yan W; Sun Y
    Front Public Health; 2021; 9():785602. PubMed ID: 35111717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?
    Gamboa AC; Liu Y; Lee RM; Zaidi MY; Staley CA; Kooby DA; Winer JH; Shah MM; Russell MC; Cardona K; Maithel SK
    J Surg Oncol; 2019 Dec; 120(8):1293-1301. PubMed ID: 31621090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program.
    Mettlin CJ; Menck HR; Winchester DP; Murphy GP
    Cancer; 1997 May; 79(10):2052-61. PubMed ID: 9149035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis.
    Sahara K; Tsilimigras DI; Mehta R; Moro A; Paredes AZ; Lopez-Aguiar AG; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Poultsides GA; Makris E; Cho C; Beems M; Dillhoff M; Maithel SK; Endo I; Pawlik TM
    Ann Surg Oncol; 2020 Apr; 27(4):1203-1212. PubMed ID: 31838609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis.
    Gupta DR; Liu Y; Jiang R; Walid S; Higgins K; Landry J; McDonald M; Willingham FF; El-Rayes BF; Saba NF
    Oncology; 2019; 97(1):49-58. PubMed ID: 31108497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients.
    Ni K; Yang JY; Baeg K; Leiter AC; Mhango G; Gallagher EJ; Wisnivesky JP; Kim MK
    Cancer Rep (Hoboken); 2021 Oct; 4(5):e1387. PubMed ID: 33835729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.
    Assi HA; Mukherjee S; Kunz PL; Machiorlatti M; Vesely S; Pareek V; Hatoum H
    Oncologist; 2020 Feb; 25(2):e276-e283. PubMed ID: 32043766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis.
    Kaslow SR; Vitiello GA; Prendergast K; Hani L; Cohen SM; Wolfgang C; Berman RS; Lee AY; Correa-Gallego C
    Ann Surg Oncol; 2022 Jun; 29(6):3522-3531. PubMed ID: 35246811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.